RARE DISEASE
Beta-thalassemia major
Beta-thalassemia major
Beta-thalassemia major
Synonyms: Cooley anemia, Mediterranean anemia
Synonyms: Cooley anemia, Mediterranean anemia
Synonyms: Cooley anemia, Mediterranean anemia
Drug discovery
4
drugs
With orphan designations
Overview
Beta-thalassemia major is a severe inherited hemoglobinopathy caused by mutations in the HBB gene, leading to reduced β-globin production, ineffective erythropoiesis, and transfusion-dependent anemia. Diagnosed in early childhood, it requires lifelong red blood cell transfusions, resulting in iron overload that necessitates chelation therapy. Complications include growth impairment, hepatosplenomegaly, endocrine dysfunction, and cardiovascular complications from iron deposition [1][3][6][16].
Key Clinical Points
Burden
Clinical: Multi-organ damage (heart, liver, endocrine) from iron overload; reduced life expectancy without optimal care [4][6][14].
Economic: Lifetime treatment costs exceed $5 million in high-income countries; lower-income regions face undertreatment due to limited resources [10][15].
Psychosocial: Impaired quality of life, chronic fatigue, and significant caregiver burden [5][9][20].
Therapies
Regular blood transfusions (every 2–4 weeks) and iron chelation therapy (deferasirox, deferiprone) [3][13].
Curative options: Allogeneic hematopoietic stem cell transplant (limited by donor availability) and gene therapy (FDA-approved CASGEVY™/Zynteglo®) [8][16].
Adjuncts: Folic acid supplementation, splenectomy in refractory cases [3][6].
Categories: rare endocrine diseases, rare genetic diseases, rare hematological diseases, rare renal diseases, rare transplant-related disorders
Research Papers
815 drug discovery papers about Beta-thalassemia major, with 4 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
815 drug discovery papers about Beta-thalassemia major, with 4 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-11 | A review on the role of Hepicidin hormone in beta thalassemia major disease
Thalassemia is a haemoglobin disorder that is inherited. One or more globin chains of haemoglobin tetramers are produced less frequently or not at all, which causes uncontrollably high RBC destruction and severe anemia. An imbalance in globin chain synthesis causes damage to red blood cells in thalassemia. Hepcidin is severely reduced in thalassemia, and any increase in hepcidin function benefits erythropoiesis and iron metabolism. Clinical trials have been conducted on synthetic hepcidin and hepcidin mimetics. Nevertheless, their efficacy/safety profile has not been satisfactory. When taking hepcidin directly as a medication, it appears to be challenging to prevent iron over-restricted erythropoiesis. Indirect methods are numerous and still evolving, each with pros and cons. Targeting erythroferrone, the primary inhibitor of hepcidin expression, is the best strategy because iron-loading anaemias significantly raise its plasma concentrations. The development of pharmacological agonists and antagonists as well as hepcidin diagnostics should enhance the management of iron diseases.
2026-07-22 | Endocrine complications of beta-thalassemia major: Primary amenorrhea as a revealing feature of hypogonadotropic hypogonadism
Beta-thalassemia major is a hereditary hemoglobinopathy requiring lifelong blood transfusions, leading to chronic iron overload responsible for multiorgan endocrine complications, of which hypogonadism is the most frequent. We report the case of a 22-year-10-month-old female patient, followed for β-thalassemia major since the age of 3, presenting with primary amenorrhea. Clinical examination revealed late-onset breast development at Tanner stage II and pubic hair at Tanner stageIV. Hormonal workup confirmed isolated hypogonadotropic hypogonadism, with the following results: estradiol<24pg/mL, follicle-stimulating hormone 1.14 uIU/mL (ref: 3.03–8.08), luteinizing hormone 0.2uIU/mL (ref:2.39–6.6), prolactin 9.8ng/ml and serum ferritin at 7288µg/L sixty times above upper limit on deferiprone 500mg, three tablets three times daily. Pituitary MRI demonstrated an age-appropriate gland with T2*-weighted-hypo-intensity consistent with pituitary siderosis, providing objective imaging evidence of iron deposition at the gonadotroph level as the underlying mechanism of central hypogonadism. Bone assessment by bone densitometry revealed osteoporosis at multiple sites. Workup for other iron overload-related endocrinopathies returned within normal limits. The patient was initiated on transdermal-17beta-estradiol at progressively increasing doses starting at0.25mg/day. The pedagogical originality of this case report lies in the association between primary amenorrhea — reflecting gonadotroph damage early enough to prevent pubertal completion — and pituitary siderosis directly visualized on MRI, offering a didactically valuable illustration of the causal link between chronic iron overload and central hypogonadotropic hypogonadism. This case underscores the importance of systematic and early endocrine screening in transfusion-dependent thalassemia patients, and highlights the need for prompt hormone replacement therapy initiation and optimized iron chelation to prevent irreversible endocrine complications.
2026-07-02 | Interleukin-1β and Glycolytic Enzyme Alterations in Beta-Thalassemia Major: Insights into Inflammation-Metabolism Crosstalk
Background: Beta-thalassemia major is characterized by chronic hemolytic anemia, ineffective erythropoiesis, and systemic iron overload, leading to metabolic and inflammatory alterations. Objective: This study investigated the relationship between serum interleukin-1β (IL-1β), key glycolytic enzymes (hexokinase [HK], pyruvate kinase [PK], phosphofructokinase [PFK]), and PFKP gene expression in beta-thalassemia major patients. Methods: A case-control study was conducted involving 42 beta-thalassemia major patients and 30 healthy controls. Serum levels of IL-1β, HK, PK, and PFK were measured using ELISA, while PFKP gene expression was assessed by RT-qPCR. Results: Patients exhibited significantly elevated IL-1β (41.34 ± 42.23 vs. 21.43 ± 26.45 pg/mL; p = 0.0276), HK (327.71 ± 282.40 vs. 131.47 ± 158.67 pg/mL; p = 0.0012), and PFK (1.83 ± 1.52 vs. 0.51 ± 0.53 ng/mL; p < 0.0001) compared to controls. Strong positive correlations were observed between IL-1β and glycolytic enzymes (r = 0.637-0.690, p < 0.0001). Conclusion: These findings demonstrate significant inflammation-metabolism crosstalk in beta-thalassemia major, suggesting that targeting inflammatory pathways may ameliorate metabolic disturbances in affected patients.
2026-06-30 | The Adverse Effects of Thalassemia Treatments Including Blood Transfusion and Main Pharmacological Therapies
A B S T R A C T Background: Beta-thalassemia major (β-TM) is a disorder which needs lifelong blood transfusions. Our aim was to examine the treatments side effects in thalassemic patients. Methods: 110 β-TM patients attending two centers were invited to the study. Those who consented were asked to complete a questionnaire. The questionnaire covered demographical information, used medications and their side effects. The data was analyzed using SPSS software version 14. Results: Data was collected between August 2008 and July 2009. Patients' age was 14.0±1.32 years. The duration of treatment was 11.3±7.5 years. Thalassemic patients received blood transfusions, deferoxamine and supportive medications. Number of medications, received by patients was 3.9±1.9. Hemosiderosis in heart (11%) and endocrine system (8%) were main blood transfusion side effects. A few had hepatitis B or C. Conclusion: Because of prevalence of side effects of therapies, reviewing and improving treatment protocol by designing new medicines with lower side effects and establishment of an adverse reactions team seemed necessary.
2026-06-22 | Diagnostic Utility of High-Performance Liquid Chromatography and Its Correlation With Hematological Indices in the Evaluation of Hemoglobinopathies.
Hemoglobinopathies are common genetic disorders in India and frequently present as microcytic hypochromic anemia, often mimicking iron deficiency anemia. High-performance liquid chromatography (HPLC) enables accurate quantification of hemoglobin fractions and facilitates reliable diagnosis. This cross-sectional study included 150 patients with microcytic hypochromic anemia (mean corpuscular volume (MCV) < 80 fL, mean corpuscular hemoglobin (MCH) < 27 pg) and clinical suspicion of hemoglobinopathy. Complete blood count and HPLC (Bio-Rad D10, Bio-Rad Laboratories, Hercules, CA) were performed. Hemoglobin fractions were quantified, and hematological indices were correlated with HPLC findings. Statistical analysis was performed using independent t-tests and chi-square tests. Abnormal hemoglobin patterns were identified in 100 (66.7%) patients. Beta thalassemia trait was the most common finding, seen in 63 patients (42.0%), and was characterized by elevated HbA2 levels (mean: 5.2% ± 0.8%). These patients showed significantly lower MCV and MCH values and higher red blood cell (RBC) counts compared with those with normal HPLC patterns (P < 0.001). Beta-thalassemia major was identified in 12 (8.0%) with markedly elevated fetal hemoglobin (HbF) (mean: 85.6% ± 8.2%). Structural variants, including HbS trait (7, 4.7%) and homozygous HbE (6, 4.0%), were also detected based on characteristic HPLC patterns. HPLC is a reliable and precise diagnostic tool for hemoglobinopathies, with a strong correlation to hematological indices. Its use enables accurate differentiation of thalassemia carriers from other causes of microcytic anemia, supporting its role in routine diagnostic evaluation.
2026-08-11 | A review on the role of Hepicidin hormone in beta thalassemia major disease
Thalassemia is a haemoglobin disorder that is inherited. One or more globin chains of haemoglobin tetramers are produced less frequently or not at all, which causes uncontrollably high RBC destruction and severe anemia. An imbalance in globin chain synthesis causes damage to red blood cells in thalassemia. Hepcidin is severely reduced in thalassemia, and any increase in hepcidin function benefits erythropoiesis and iron metabolism. Clinical trials have been conducted on synthetic hepcidin and hepcidin mimetics. Nevertheless, their efficacy/safety profile has not been satisfactory. When taking hepcidin directly as a medication, it appears to be challenging to prevent iron over-restricted erythropoiesis. Indirect methods are numerous and still evolving, each with pros and cons. Targeting erythroferrone, the primary inhibitor of hepcidin expression, is the best strategy because iron-loading anaemias significantly raise its plasma concentrations. The development of pharmacological agonists and antagonists as well as hepcidin diagnostics should enhance the management of iron diseases.
2026-07-22 | Endocrine complications of beta-thalassemia major: Primary amenorrhea as a revealing feature of hypogonadotropic hypogonadism
Beta-thalassemia major is a hereditary hemoglobinopathy requiring lifelong blood transfusions, leading to chronic iron overload responsible for multiorgan endocrine complications, of which hypogonadism is the most frequent. We report the case of a 22-year-10-month-old female patient, followed for β-thalassemia major since the age of 3, presenting with primary amenorrhea. Clinical examination revealed late-onset breast development at Tanner stage II and pubic hair at Tanner stageIV. Hormonal workup confirmed isolated hypogonadotropic hypogonadism, with the following results: estradiol<24pg/mL, follicle-stimulating hormone 1.14 uIU/mL (ref: 3.03–8.08), luteinizing hormone 0.2uIU/mL (ref:2.39–6.6), prolactin 9.8ng/ml and serum ferritin at 7288µg/L sixty times above upper limit on deferiprone 500mg, three tablets three times daily. Pituitary MRI demonstrated an age-appropriate gland with T2*-weighted-hypo-intensity consistent with pituitary siderosis, providing objective imaging evidence of iron deposition at the gonadotroph level as the underlying mechanism of central hypogonadism. Bone assessment by bone densitometry revealed osteoporosis at multiple sites. Workup for other iron overload-related endocrinopathies returned within normal limits. The patient was initiated on transdermal-17beta-estradiol at progressively increasing doses starting at0.25mg/day. The pedagogical originality of this case report lies in the association between primary amenorrhea — reflecting gonadotroph damage early enough to prevent pubertal completion — and pituitary siderosis directly visualized on MRI, offering a didactically valuable illustration of the causal link between chronic iron overload and central hypogonadotropic hypogonadism. This case underscores the importance of systematic and early endocrine screening in transfusion-dependent thalassemia patients, and highlights the need for prompt hormone replacement therapy initiation and optimized iron chelation to prevent irreversible endocrine complications.
2026-07-02 | Interleukin-1β and Glycolytic Enzyme Alterations in Beta-Thalassemia Major: Insights into Inflammation-Metabolism Crosstalk
Background: Beta-thalassemia major is characterized by chronic hemolytic anemia, ineffective erythropoiesis, and systemic iron overload, leading to metabolic and inflammatory alterations. Objective: This study investigated the relationship between serum interleukin-1β (IL-1β), key glycolytic enzymes (hexokinase [HK], pyruvate kinase [PK], phosphofructokinase [PFK]), and PFKP gene expression in beta-thalassemia major patients. Methods: A case-control study was conducted involving 42 beta-thalassemia major patients and 30 healthy controls. Serum levels of IL-1β, HK, PK, and PFK were measured using ELISA, while PFKP gene expression was assessed by RT-qPCR. Results: Patients exhibited significantly elevated IL-1β (41.34 ± 42.23 vs. 21.43 ± 26.45 pg/mL; p = 0.0276), HK (327.71 ± 282.40 vs. 131.47 ± 158.67 pg/mL; p = 0.0012), and PFK (1.83 ± 1.52 vs. 0.51 ± 0.53 ng/mL; p < 0.0001) compared to controls. Strong positive correlations were observed between IL-1β and glycolytic enzymes (r = 0.637-0.690, p < 0.0001). Conclusion: These findings demonstrate significant inflammation-metabolism crosstalk in beta-thalassemia major, suggesting that targeting inflammatory pathways may ameliorate metabolic disturbances in affected patients.
2026-06-30 | The Adverse Effects of Thalassemia Treatments Including Blood Transfusion and Main Pharmacological Therapies
A B S T R A C T Background: Beta-thalassemia major (β-TM) is a disorder which needs lifelong blood transfusions. Our aim was to examine the treatments side effects in thalassemic patients. Methods: 110 β-TM patients attending two centers were invited to the study. Those who consented were asked to complete a questionnaire. The questionnaire covered demographical information, used medications and their side effects. The data was analyzed using SPSS software version 14. Results: Data was collected between August 2008 and July 2009. Patients' age was 14.0±1.32 years. The duration of treatment was 11.3±7.5 years. Thalassemic patients received blood transfusions, deferoxamine and supportive medications. Number of medications, received by patients was 3.9±1.9. Hemosiderosis in heart (11%) and endocrine system (8%) were main blood transfusion side effects. A few had hepatitis B or C. Conclusion: Because of prevalence of side effects of therapies, reviewing and improving treatment protocol by designing new medicines with lower side effects and establishment of an adverse reactions team seemed necessary.
2026-06-22 | Diagnostic Utility of High-Performance Liquid Chromatography and Its Correlation With Hematological Indices in the Evaluation of Hemoglobinopathies.
Hemoglobinopathies are common genetic disorders in India and frequently present as microcytic hypochromic anemia, often mimicking iron deficiency anemia. High-performance liquid chromatography (HPLC) enables accurate quantification of hemoglobin fractions and facilitates reliable diagnosis. This cross-sectional study included 150 patients with microcytic hypochromic anemia (mean corpuscular volume (MCV) < 80 fL, mean corpuscular hemoglobin (MCH) < 27 pg) and clinical suspicion of hemoglobinopathy. Complete blood count and HPLC (Bio-Rad D10, Bio-Rad Laboratories, Hercules, CA) were performed. Hemoglobin fractions were quantified, and hematological indices were correlated with HPLC findings. Statistical analysis was performed using independent t-tests and chi-square tests. Abnormal hemoglobin patterns were identified in 100 (66.7%) patients. Beta thalassemia trait was the most common finding, seen in 63 patients (42.0%), and was characterized by elevated HbA2 levels (mean: 5.2% ± 0.8%). These patients showed significantly lower MCV and MCH values and higher red blood cell (RBC) counts compared with those with normal HPLC patterns (P < 0.001). Beta-thalassemia major was identified in 12 (8.0%) with markedly elevated fetal hemoglobin (HbF) (mean: 85.6% ± 8.2%). Structural variants, including HbS trait (7, 4.7%) and homozygous HbE (6, 4.0%), were also detected based on characteristic HPLC patterns. HPLC is a reliable and precise diagnostic tool for hemoglobinopathies, with a strong correlation to hematological indices. Its use enables accurate differentiation of thalassemia carriers from other causes of microcytic anemia, supporting its role in routine diagnostic evaluation.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
4 orphan drug designations for Beta-thalassemia major.
4 orphan drug designations for Beta-thalassemia major.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Human apotransferrin | proteins | EMA | 2018-11-19 | — | Sanquin Plasma Products B.V. |
Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene | gene therapies | EMA | 2016-05-30 | — | Fondazione Telethon Ets |
2,2-dimethylbutyric acid, sodium salt | small molecules | EMA | 2009-02-27 | — | Isabelle Ramirez |
deferoxamine starch conjugate | small molecules | FDA | 1998-12-21 | — | Biomedical Frontiers, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.